Data protection Impressum

Biotech

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (February 2025)

25 February 2025

Vaud-based biopharma Oculis has successfully completed an oversubscribed USD 100 million offering, further strengthening its pipeline of innovative ophthalmic and neuro-ophthalmic treatments.

Oculis secures USD 100 million to advance its neuroprotective treatment pipeline

17 February 2025

The Deep Tech Nation Switzerland Foundation and the Startupticker Foundation have launched the Deep Tech Nation Information Platform, a central resource aimed at enhancing venture capital investment in Swiss deep tech start-ups.

Launch of the Swiss Deep Tech Information Platform

10 February 2025

Biotech company CELLnTEC is playing a key role in the NEOLIVER project, a European-Swiss initiative developing the world’s first autologous bioprinted liver for clinical use. The project, co-funded by the EU and the Swiss government, aims to address the global organ donor shortage through innovative bioprinting technologies.

Bern-based CELLnTEC joins NEOLIVER project to develop bioprinted liver constructs

10 February 2025

Swiss start-ups raised CHF 2.4 billion in venture capital in 2024, marking an 8.5% decline from the previous year. The number of financing rounds also fell for the first time, reflecting a challenging investment climate. Despite these setbacks, biotech and cleantech sectors saw strong growth, and investor sentiment remains optimistic for 2025.

Swiss start-ups secure CHF 2.4 billion in 2024 amid shifting investment trends

4 February 2025

The Swiss Institute of Bioinformatics has inaugurated the Centre for Pathogen Bioinformatics in Bern, a state-of-the-art facility dedicated to strengthening genomic surveillance of infectious diseases.

The Centre for Pathogen Bioinformatics was inaugurated in Bern

4 February 2025

The Lausanne University Hospital (CHUV) has secured market authorization from Swissmedic to produce a fecal microbiota transplant (FMT) medication, making it the first accredited center in Switzerland to manufacture this treatment under strict pharmaceutical standards. This breakthrough provides an effective solution for patients suffering from recurrent Clostridioides difficile infections, a debilitating condition characterized by repeated digestive blowouts and severe discomfort.

CHUV becomes first Swiss hospital to produce gut-balancing medication

29 January 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (January 2025)

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

Lyncée Tec, a leader in Digital Holographic Microscope (DHM) technology, has been acquired by Park Systems, a South Korean nanometrology pioneer. This strategic move enhances Park Systems' optical metrology offerings and expands their capabilities in semiconductor applications.

Lyncée Tec joins forces with South Korea’s Park Systems

15 January 2025

1 2 3 4 5 6 7 8 … 22